MAPLE GROVE, Minn. and SAN FRANCISCO, Dec. 3, 2019 /PRNewswire/ — StemoniX, Inc. and Atomwise Inc. as we speak introduced a three way partnership that mixes StemoniX’s human microOrgan® platform with Atomwise’s AI know-how to allow the speedy discovery and growth of novel small molecule therapies. The three way partnership will initially goal Rett syndrome, a uncommon neurodevelopmental illness.

Rett syndrome is a extreme neurological dysfunction on account of mutations within the MECP2 gene. The dysfunction usually manifests in toddler women and ends in impairment of mental and motor growth, seizures, and lack of speech. There is no such thing as a identified treatment for Rett syndrome. 

StemoniX is a pacesetter in growing fashions for particular ailments by way of its microOrgan platform, the world’s first ready-to-use assay plates containing residing microtissues engineered from human induced pluripotent stem cells (iPSC). Atomwise is the chief in utilizing synthetic intelligence (AI) for small molecule drug discovery. Within the three way partnership, Atomwise will use its AI know-how to research billions of compounds to establish potent and selective binders for proteins which can be necessary for Rett syndrome. StemoniX will check the compounds on its human microBrain® 3D illness mannequin of Rett syndrome to find out organic efficacy.

Conventional drug discovery and early drug growth require hundreds of analysis hours and tens of millions of {dollars} to establish a possible therapeutic for medical growth. Regardless of the time and expense, the overwhelming majority of potential medicine – 90% – in the end fail within the clinic. The excessive prices and excessive failure charge usually make it infeasible to pursue drug discovery and growth for uncommon ailments. It’s particularly difficult for uncommon neurological ailments as a result of complexity of human mind operate, which isn’t properly replicated in animal fashions.

Subsequent technology applied sciences, resembling AI and human microOrgans, have the potential to rework the pace of drug discovery. The mixture of AI with human microOrgans can scale back each time and value whereas rising the prospect of medical success by specializing in solely these compounds with novel chemical constructions which can be predicted to be simplest in a related human system. Streamlined efforts with quicker growth occasions and decrease failure charges are vital for the invention of recent therapies for sufferers with uncommon and difficult neurological ailments resembling Rett syndrome.

“The three way partnership brings collectively the complementary applied sciences of StemoniX and Atomwise, creating a chance to go from mannequin to molecule to validated drug in a fraction of the time and value required with conventional strategies,” mentioned Ping Yeh, StemoniX Co-founder and CEO. “Atomwise is a superb companion for a notoriously difficult illness space. Their experience will allow drug discovery on traditionally undruggable targets and supply new alternatives for treating uncommon neurological ailments.”

“New applied sciences and approaches are important to handle the wants of sufferers,” mentioned Abraham Heifets, Ph.D., Co-founder and CEO of Atomwise. “StemoniX has made outstanding progress with their microBrain 3D platform and its software to Rett syndrome.  It’s a probably highly effective device to quickly consider compound efficacy and assess their suitability for medical trials, and we’re excited to companion with them.” 

About StemoniX
StemoniX is accelerating the invention of recent medicines to deal with difficult ailments by way of the world’s first ready-to-use assay plates containing residing human microOrgans®, together with electrophysiologically energetic neural (microBrain®) and cardiac (microHeart®) cells. Predictive, correct, and constant, StemoniX’s merchandise mixed with its proprietary information administration and analytical instruments (AnalytiXTM) are revolutionizing conventional drug discovery and growth by radically bettering the pace, accuracy, and prices required to establish new medicine and conduct preliminary human toxicity and efficacy testing. By way of its Discovery as a Service providing, the corporate companions with organizations to display compounds in addition to to create personalized microOrgan fashions and assays tailor-made to particular discovery and toxicity wants. Go to www.stemonix.com to find out how StemoniX helps international establishments humanize drug discovery and growth to convey essentially the most promising medicines to sufferers.

About Atomwise
Atomwise Inc. invented the primary deep studying AI know-how for structure-based small molecule drug discovery. Created in 2012, as we speak Atomwise performs a whole bunch of initiatives per yr in partnership with a number of the world’s largest pharmaceutical and agrochemical corporations, in addition to greater than 200 universities and hospitals in 40 nations. Atomwise has raised over $50 million from main enterprise capital companies to help the event and software of its AI know-how. Study extra at atomwise.com or comply with @AtomwiseInc.

StemoniX Investor Contact:
Maureen McEnroe, CFA
+1.212.375.2664
mmcenroe@tiberend.com  

StemoniX Media Contact:
Ingrid Mezo
+1.646.604.5150
imezo@tiberend.com

Atomwise Media Contact:
Steph Rosenbloom
+1.646.634.7954
media@atomwise.com

SOURCE StemoniX

Associated Hyperlinks

http://www.stemonix.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here